(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 20.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Aurinia Pharmaceuticals's revenue in 2026 is $265,808,000.On average, 9 Wall Street analysts forecast AUPH's revenue for 2026 to be $43,955,642,371, with the lowest AUPH revenue forecast at $39,088,088,932, and the highest AUPH revenue forecast at $49,763,218,995. On average, 8 Wall Street analysts forecast AUPH's revenue for 2027 to be $50,767,844,054, with the lowest AUPH revenue forecast at $45,102,655,234, and the highest AUPH revenue forecast at $62,566,255,679.
In 2028, AUPH is forecast to generate $60,613,697,000 in revenue, with the lowest revenue forecast at $51,681,499,128 and the highest revenue forecast at $75,890,062,572.